RxDoctor Payments DataLook up a doctor →

James Demaio, MD

Infectious Disease · Bradenton, FLNPI 1154322717

Payments from drug & device makers

$901,619in general payments, 2019–2025

Across 198 payments — averaging $4553.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$642K
  • AstraZeneca$148K
  • Insmed, Inc.$110K
  • Paratek Pharmaceuticals, Inc.$562
  • AbbVie$323
  • Aimmune Therapeutics, Inc.$214
  • plus $606 from 6 others

What the payments were for

  • Food & beverage$2,34996%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$901,619 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$675,869
Medicare patients
610
Services billed
192,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate17$189,667
ArikayceAmikacin Liposomal/Neb.Accessr12$180,406
TivicayDolutegravir Sodium30$67,952
DescovyEmtricitabine/Tenofov Alafenam29$63,729
BiktarvyBictegrav/Emtricit/Tenofov Ala14$61,871
Rifabutin24$10,578
Ethambutol Hcl72$5,149
Rifampin48$2,193
Doxycycline Hyclate50$1,719
Azithromycin84$1,709
Cefepime Hcl13$1,514
CefuroximeCefuroxime Axetil42$1,488
Doxycycline Monohydrate17$904
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$826
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$562$189,66717 claims
Insmed, Inc.Arikayce$109,888$180,40612 claims
GileadDescovy, Biktarvy$118$125,60043 claims
Viiv Healthcare CompanyTivicay$24$67,95230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →